Simulations Plus Announces Leadership Changes at Cognigen
October 02 2019 - 8:30AM
Business Wire
Jill Fiedler-Kelly named President along
with other promotions and key additions
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of
modeling and simulation solutions for the pharmaceutical,
biotechnology, chemicals, and consumer goods industries, today
announced that Jill Fiedler-Kelly has been named President of the
Cognigen division in addition to other leadership changes to
support the ongoing growth of the Company’s Cognigen division.
Ms. Jill Fiedler-Kelly, a co-founder of Cognigen who served as
Vice President of Pharmacometric Services since 1992, has been
promoted to President of the Cognigen division of Simulations Plus.
Ms. Fiedler-Kelly has more than 25 years of experience in the
design and implementation of pharmacometric modeling and simulation
approaches in drug development programs and in providing training
and instruction in pharmacometric modeling. She is an Adjunct
Professor of Pharmaceutical Sciences at the University at Buffalo
and co-authored the book Introduction to Population PK/PD Analysis
with Nonlinear Mixed Effects Models with Joel Owen. In 2016, Ms.
Fiedler-Kelly was named Fellow of the International Society of
Pharmacometrics.
In July 2019, Dr. Kevin Dykstra joined the Company as Vice
President, Consulting Services, and has assumed a key leadership
role in the Company’s consulting services. Dr. Dykstra has
more than 25 years of cumulative experience in the Pharmaceutical
and Biotechnology industry providing strategic pharmacometric
modeling and simulation services. Prior to joining the Company, Dr.
Dykstra co-founded qPharmetra in 2010, and before that spent 10
years with Pharsight Corporation and Certara. He conducted
post-doctoral work as a Staff Fellow at the National Institutes of
Health. He holds MS and PhD degrees in Chemical Engineering from
the University of Michigan and undergraduate degrees in Chemical
Engineering and German from the University of Colorado with
additional training in Biostatistics from Boston University. Dr.
Dykstra is a Fellow of the American College of Clinical
Pharmacology.
Dr. Joel Owen has been promoted to Vice President,
Pharmacometric Services. Dr. Owen has been at Cognigen since 2017
and previously served as Director of PK/PD at Cognigen from 2001 to
2008. From 2008 to 2017, Dr. Owen was Professor of Pharmaceutics at
Union University in Jackson, Tennessee, where he is currently an
Adjunct Professor. Dr. Owen co-authored Introduction to Population
PK/PD Analysis with Nonlinear Mixed Effects Models with Ms.
Fiedler-Kelly. He holds a BS degree in Pharmacy and a PhD degree in
Pharmaceutical Sciences from Auburn University. Dr. Owen was a
Fulbright Specialist from 2013 to 2017 and has regularly taught
workshops at Makerere University in Kampala, Uganda.
Dr. Alexander (Al) Berg has been promoted to Vice President,
Operations. Dr. Berg joined Cognigen earlier this year from the
Critical Path Institute (C-Path) where he served as scientific
director for the Critical Path to Tuberculosis Drug Regimens
Initiative, a global health partnership with the Bill and Melinda
Gates Foundation. Prior to C-Path, Dr. Berg was a clinical
pharmacology and pharmacometrics lead at Upsher-Smith Laboratories
and completed a fellowship in Clinical Pharmacology at the Mayo
Clinic. Dr. Berg holds BS, PhD and Doctor of Pharmacy degrees in
Pharmaceutical Sciences from North Dakota State University. He is a
Fellow of the American College of Clinical Pharmacology, an Adjunct
Professor at the University of Minnesota, and an Invited Lecturer
to the Mayo Clinic.
Dr. Ted Grasela, Founder and former President of Cognigen,
continues with the Company as Executive Vice President. In this
role, Dr. Grasela will provide support to Ms. Fiedler-Kelly and
continue to provide strategic consulting support to our key
clients.
“Jill Fiedler-Kelly has been a key member of the Cognigen team
from its beginning as a Founder through to leadership of the
consulting practice since its acquisition by Simulations Plus,”
said Shawn O’Connor, chief executive officer of Simulations Plus.
“Her knowledge of the business, the respect of Cognigen staff she
has earned during her tenure with the company, and her stature in
the industry and amongst our clients, uniquely positions her to
assume leadership of the division. Under Ms. Fiedler-Kelly’s
leadership, combined with the other recent promotions and additions
announced today, we are well positioned to continue our success at
Cognigen.”
“I am both honored and excited to take on this new challenge of
leading the outstanding and dedicated team at Cognigen through the
next stage of our growth,” said Ms. Fiedler-Kelly. “I am truly
grateful for the excellent mentorship and guidance Dr. Grasela has
provided over the years and am very happy for his continuing
support. I look forward to working together with the leadership of
Simulations Plus and DILIsym Services to support new and existing
clients in overcoming their drug development and regulatory hurdles
using advanced modeling and simulation services and software, and
to continuing to grow and expand our services.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of drug discovery
and development software as well as a leading provider of both
preclinical and clinical pharmacometric consulting services for
regulatory submissions and quantitative systems pharmacology models
for drug-induced liver injury and nonalcoholic fatty liver disease.
The company is a global leader focused on improving the ways
scientists use knowledge and data to predict the properties and
outcomes of pharmaceutical, biotechnology, and chemical agents. Our
software is licensed and used in the conduct of drug research by
major pharmaceutical, biotechnology, chemical, and consumer goods
companies and regulatory agencies worldwide. Our innovations in
integrating new and existing science in medicinal chemistry,
computational chemistry, pharmaceutical science, biology, and
physiology into our software have made us the leading software
provider for physiologically based pharmacokinetic modeling and
simulation. For more information, visit our website at
www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect,” and “anticipate”
mean that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
as filed with the U.S. Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191002005344/en/
Simulations Plus Investor Relations
Ms. Renee Bouche 661-723-7723 renee@simulations-plus.com
Hayden IR Mr. Cameron Donahue
651-653-1854 cameron@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Sep 2023 to Sep 2024